Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00026004
DRKS00026004
Recruiting
N/A

Prospective clinical investigation of the effects of bariatric surgery on nocturnal hypoxaemic burden in patients with severe obesity - BASH

Klinikum Saarbrücken0 sites100 target enrollmentAugust 19, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsE66.02G47.9Sleep disorder, unspecified

Overview

Phase
N/A
Intervention
Not specified
Conditions
E66.02
Sponsor
Klinikum Saarbrücken
Enrollment
100
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 19, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Klinikum Saarbrücken

Eligibility Criteria

Inclusion Criteria

  • •Indication for bariatric surgery according to the S3 guideline: Surgery of obesity and metabolic diseases
  • •The patient is fully informed and agrees to participate in the study
  • •The surgical indication has been secured by a multidisciplinary team consisting of a nutritionist, surgeon, psychosomatic specialist / psychologist and, if necessary a general doctor.

Exclusion Criteria

  • •Consent to participate in the study has not been given or will be revoked.
  • •Bariatric surgery is not performed.
  • •Previously known severe chronic respiratory failure requiring oxygen therapy
  • •General inoperability
  • •Contraindication to bariatric surgery according to the S3 guideline: Surgery for obesity and metabolic diseases:
  • •\- Unstable psychopathological conditions, untreated bulimia nervosa, active substance dependence
  • •\- Consuming underlying diseases, malignant neoplasms, untreated endocrine causes, chronic diseases worsened by a postoperative catabolic metabolism
  • •\- Present or planned pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
Clinical prospective study to investigate efficacy and safety of immune-cell therapy for malignant tumorsMalignant tumor
JPRN-UMIN000004610Kanazawa university600
Completed
N/A
Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.
JPRN-UMIN000008046Seta Clinic Group20
Completed
N/A
Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapyMalignant tumor (all HLA types)
JPRN-UMIN000009447Seta Clinic Group5
Active, Not Recruiting
Phase 1
A Study of RoActemra/Actemra (tocilizumab) in Comparison to Enbrel (etanercept) in Patients With Rheumatoid Arthritis and Increased Risk for Heart Disease.Rheumatoid ArthritisMedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2010-020065-24-ESF. Hoffmann-La Roche Ltd.2,800
Active, Not Recruiting
Phase 1
A Study of RoActemra/Actemra (tocilizumab) in Comparison to Enbrel (etanercept) in Patients With Rheumatoid Arthritis and Increased Risk for Heart Disease.Rheumatoid ArthritisMedDRA version: 16.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2010-020065-24-BEF. Hoffmann-La Roche Ltd.3,080